Gefitinib is an EGFR tyrosine kinase inhibitor that can hinder tumor cell proliferation and angiogenesis and has been commercially applied in treating non-small-cell lung cancer [51]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.